![SAB Biotherapeutics, Inc. logo](/logos/SABS.webp)
SAB Biotherapeutics, Inc.
NASDAQ:SABS
Overview | Financials
Company Name | SAB Biotherapeutics, Inc. |
Symbol | SABS |
Currency | USD |
Price | 2.18 |
Market Cap | 20,119,809 |
Dividend Yield | 0% |
52-week-range | 2 - 6.3 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Eddie Joe Sullivan Ph.D. |
Website | https://www.sabbiotherapeutics.com |
An error occurred while fetching data.
About SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD